<DOC>
	<DOC>NCT00985790</DOC>
	<brief_summary>The purpose of the present study is to assess the immunogenicity and safety of vaccine GSK2321138A in children.</brief_summary>
	<brief_title>Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>For all subjects: Subjects who the investigator believes that they and/or their Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol. Written informed consent obtained from the subject/from the LAR(s). For unprimed subjects: A male or female child aged 18 to 47 months at the time of the first vaccination. Children who did not have influenza vaccine in a previous season. For primed subjects from study NCT00764790: • Children who received Fluarix™ in the 111751 study NCT00764790. Use of any investigational or nonregistered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period. History of hypersensitivity to any vaccine. History of allergy or reactions likely to be exacerbated by any component of the vaccine. Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before and ending 28 days after each dose of vaccine(s). Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history and physical examination. Acute disease at the time of enrolment. History of Guillain Barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine. Receipt of another seasonal influenza vaccine outside of this study, during current (20092010) flu season. Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination. Chronic administration of immunosuppressants or other immunemodifying drugs within six months prior to the first vaccination Inhaled and topical steroids are allowed. Administration of immunoglobulins and/or blood products within the 3 month preceding the first dose of study vaccine or planned administration during the study period. Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a noninvestigational product.</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>47 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>vaccine</keyword>
	<keyword>Influenza</keyword>
</DOC>